Rotavirus Infections Clinical Trial
Official title:
SaniVac Trial: An Assessment of Oral Rotavirus Vaccine Performance Among Infants Enrolled in a Controlled Before-after Study in Low-income Neighbourhoods of Maputo, Mozambique
This is a controlled cohort study to assess the effect of improved sanitation on oral rotavirus vaccine performance in low-income urban neighbourhoods of Maputo, Mozambique. The specific hypotheses are that: (1) access to improved sanitation is associated with increased oral rotavirus vaccine immunogenicity; (2) enteric infection concurrent to oral rotavirus vaccination is associated with reduced oral rotavirus vaccine immunogenicity; and (3) Environmental Enteric Dysfunction is associated with reduced oral rotavirus vaccine immunogenicity. Pregnant women will be enrolled from the intervention and control arms of a previous sanitation trial (NCT02362932) post-intervention and will be enrolled at no later than eight months' gestation and then followed to 4 months of age of the infant. Blood samples and faeces will be taken from the infant at the time of administration of the first dose of the oral rotavirus vaccine and four weeks after the second dose of the vaccine. The primary outcome of interest in the study is oral rotavirus vaccine immunogenicity among participating vaccinated infants. Seroconversion is defined as a ≥ fourfold rise in serum anti-rotavirus IgA titers between first dose of oral RV vaccine and 4 weeks (+/- 1 week) after second dose of oral RV vaccine. Enteric infections are defined as the presence of ≥ 1 of the following enteric infections in stool: adenovirus 40/41, rotavirus A, norovirus GI/GII, Salmonella spp. (including serovars Typhi and Paratyphi), Campylobacter spp. (C. jejuni, C. coli, C. lari), Shigella spp. (S. boydii, S. sonnei, S. flexneri, S. dysenteriae), Clostridium difficile Toxin A/B, enterotoxigenic Escherichia coli (ETEC) LT/ST, E. coli O157, Shiga-like toxin-producing E. coli (STEC) stx1/stx2, Yersinia enterocolitica, Vibrio cholerae, Giardia lamblia, Entamoeba histolytica, and Cryptosporidium spp. (C. parvum, C. hominis). Environmental Enteric Dysfunction is measured via a combined disease activity score including faecal markers of intestinal inflammation and permeability: neopterin, α-1 antitrypsin, and myeloperoxidase in stool.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
| Completed |
NCT02220439 -
Does the Fecal Microbiome Influence Rotarix Immunogenicity
|
N/A | |
| Withdrawn |
NCT00757926 -
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT00484952 -
Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel
|
N/A | |
| Completed |
NCT00092443 -
Dose Confirmation Efficacy Study (V260-007)
|
Phase 3 | |
| Terminated |
NCT01357174 -
ROTATEQ™ Post-Marketing Surveillance in the Philippines
|
N/A | |
| Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
| Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT06080906 -
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
|
Phase 2 | |
| Completed |
NCT02542462 -
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
|
Phase 4 | |
| Completed |
NCT00346892 -
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV
|
Phase 2 | |
| Not yet recruiting |
NCT05212935 -
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
|
||
| Completed |
NCT00092456 -
Consistency Lots Vaccine Study (V260-009)
|
Phase 3 | |
| Completed |
NCT00981669 -
Rotavirus Vaccine Produced by Butantan Institute
|
Phase 1 | |
| Completed |
NCT05037435 -
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.
|
Phase 3 | |
| Completed |
NCT03483116 -
A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine
|
Phase 2 | |
| Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A | |
| Active, not recruiting |
NCT05621655 -
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
|
Phase 2 | |
| Completed |
NCT00280111 -
Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants
|
Phase 1 | |
| Completed |
NCT00090233 -
Rotavirus Efficacy and Safety Trial (REST)(V260-006)
|
Phase 3 |